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Summary

Material/Methods:

The catalytic contribution of four conserved histidines of human coproporphyrinogen oxidase
(CPO) has been investigated using site-directed mutagenesis to change histidine (H) into alanine
(A).
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Background:

BR

The wild-type and mutant enzyme forms were analyzed for their ability to utilize coproporphyrinogen-III, mesoporphyrinogen-VI, and harderoporphyrinogen as substrates.
Wild-type CPO had speciﬁc activities of 4.9±0.9 nmole product/min/mg for coproporphyrinogen-III, 1.7±0.7 nmole product/min/mg for mesoporphyrinogen-VI, and 5.1±1.8 nmole product/min/mg for harderoporphyrinogen. The four mutant enzymes were catalytically competent
with all three substrates, but to varying degrees. The most affected mutant was the H158A enzyme
which exhibited approximately 50-fold lower activity than wild-type recombinant CPO.

Conclusions:

Thus, His158 of human CPO may have a role in the active site, but none of the conserved histidine
residues of human coproporphyrinogen oxidase is essential for catalytic activity although changes
in histidines have been implicated in the disease state hereditary coproporphyria.
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Results:
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Catalysis by CPO is poorly understood at the molecular level.
The roles of speciﬁc amino acids in catalysis by human CPO
have not yet been elucidated. Histidines are common proton donors and acceptors in biological catalysis, and therefore their involvement in the catalytic mechanism of CPO is
reasonable to assess. Conserved His158 was previously proposed to play a critical role in metal coordination in mouse
CPO [19]. Subsequently, however, human CPO was found
to not require metal ions for catalysis [3].

O
N

Heme and related porphyrins serve as important prosthetic groups in a number of biologically critical proteins, including hemoglobin, essential for oxygen transport in the
blood, and the cytochromes, important in electron transport in the mitochondria of eukaryotic cells. Heme biosynthesis is accomplished through a series of eight enzyme-catalyzed reactions. The Shemin pathway (of plants and animals)
starts with the relatively simple molecules glycine and succinyl coenzyme A, and ends with a heme molecule containing four pyrrole rings linked by methine bridges capable
of coordinating a ferrous (Fe2+) ion. Coproporphyrinogen
oxidase (CPO; EC 1.3.3.3) is the sixth enzyme of the heme
biosynthetic pathway, catalyzing the sequential oxidative
decarboxylation (Figure 1A) of two propionate groups of
coproporphyrinogen-III to vinyl groups to yield protoporphyrinogen-IX [1,2]. This is a two-step process for which
the monovinyl intermediate (harderoporphyrinogen) has
been well established. The enzyme from aerobic organisms
requires molecular oxygen, but no other known cofactor
is required. Medlock and Dailey [3] speciﬁcally and convincingly report that the recombinant human enzyme expressed in Escherichia coli is not a metalloprotein. In addition to the authentic substrate, synthetic analogues have also
been evaluated as substrates for CPO. MesoporphyrinogenVI (Figure 1B) has been shown to be a substrate for this
enzyme but only undergoes the ﬁrst oxidative decarboxylation [4,5].

ary origin of the enzymes in this family. Certain amino acids have been conserved in evolution, suggesting a critical
role in the function of the protein. Among the conserved
amino acids of aerobic CPO are four histidines, an amino
acid previously implicated as potentially critical for catalysis
by chemical modiﬁcation studies [21]. Shown in Figure 2 is
an alignment of CPO amino acid sequences from seven representative organisms. Among these seven sequences, the
overall amino acid sequence identity is 26%. Identical amino acids are shaded in black while the four conserved histidines at positions 148, 158, 197, and 227 are indicated by
the asterisks. The human and the mouse genes are highly
conserved with both having the four conserved histidines
as compared by Medlock and Dailey [3].
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BACKGROUND

This study investigated the contribution of four conserved
histidines to catalysis by human coproporphyrinogen oxidase by substituting histidine (H) at position 148, 158, 197,
or 227 with alanine (A) using site-directed mutagenesis.
The wild-type and mutant forms of the recombinant enzyme were expressed in E. coli, puriﬁed to electrophoretic
homogeneity, and analyzed for the ability to utilize coproporphyrinogen-III, harderoporphyrinogen, and mesoporphyrinogen-VI as substrates for catalysis. Use of the three
different substrates allows for comparison of rates for the
ﬁrst and second decarboxylations. For the most interesting
histidine mutant (H158A), enzyme kinetics were also carried out to determine Km, Vmax, kcat and kcat/Km, and these
were compared to the values obtained for the recombinant
human wild-type enzyme.
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Coproporphyrinogen oxidase deﬁciency in humans leads
to the disease state hereditary coproporphyria (HCP). In
HCP, CPO activity is often signiﬁcantly reduced, and afﬂicted HCP individuals suffer from neurological disturbances
and cutaneous photosensitivity [6,7]. The gene encoding
human CPO is located on chromosome 9 [8] and genome
sequencing efforts have revealed mutations in the CPO gene
that lead to HCP [9,10]. In mammals, CPO is expressed as
a 40 kDa precursor, and contains an amino terminal mitochondrial targeting signal. After proteolytic processing, the
protein is present as a mature 37 kDa form [10–12]. CPO is
reported to be located in the intermembrane space of the
mitochondria and possesses the ability to associate with the
mitochondrial inner membrane [1,13].
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Coproporphyrinogen oxidase from both prokaryote and
eukaryote organisms has been studied, including yeast
[14,15], chicken erythrocytes [16], mouse liver [17], and
bovine liver [18]. In addition to the isolation of CPO from
bovine liver, mouse liver, and yeast, recombinant human
[3] and mouse CPO [19] have been puriﬁed. Studies investigating the chemical modiﬁcation of speciﬁc amino acids have implicated tyrosine, arginine, histidine and lysine
residues as playing a signiﬁcant role in catalysis or protein
structure [16,20,21].
Modern molecular biological techniques and genome sequencing projects have facilitated the inﬂux of a tremendous amount of nucleotide sequence data. A search of current nucleotide and protein databases reveals more than
20 putative CPO sequences, from organisms as diverse as
mammals, plants, insects, yeast, enterobacteria, and cyanobacteria. An alignment of the available CPO amino acid
sequences is useful for assessing the common evolution-

MATERIAL AND METHODS
Material
The polymerase chain reaction was performed using oligonucleotide primers and Platinum Pfx DNA Polymerase from
Invitrogen. Expression vector pET21d was obtained from
Novagen. Restriction endonucleases were purchased from
New England Biolabs. T4 DNA Ligase was from Promega and
isopropyl-b-D-thiogalactoside (IPTG) was from Eppendorf.
Clontech was the source of TALON metal afﬁnity resin.
Protease inhibitors were from Sigma. Qiaprep spin miniprep and Qiaex II gel extraction kits were from Qiagen.
Automated ﬂuorescent sequencing was performed on an ABI
377 sequencer using a BigDye terminator DNA sequencing
kit from Applied Biosystems. Tryptone, yeast extract, sodium
chloride, chloramphenicol, and ampicillin were purchased
from Fisher. The Protein Assay Kit was from Bio-Rad.
Construction of expression vector pET21d-CPO
The pET inducible protein expression system was
used for large-scale production of recombinant CPO.
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Figure 1. Reactions catalyzed by coproporphyrinogen oxidase. (A) conversion of coproporphyrinogen-III to protoporphyrinogen-IX via
harderoporphyrinogen, a monovinyl intermediate. (B) conversion of mesoporphyrinogen-VI to the monovinyl product.
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82
114
92
120
45
37
54

ER-KEGGGGISCVLQDGCVFEKAGVSISVVHGNLSEEAAKQMRSRGKVLKTKD------SR-PGGGGGISRVLQDGNVFEKAGVNVSVVYGVMPPEAYRAAKGSASDQKP--------TR-PGGGGGISRVLQDGNVWEKAGVNVSVVYGTMPPEAYRAATGNAEKLKNKGDG----ER-PEGGGGITCVLQDGDVFEKAGVNISVVTGSLPPAAVQQMRARGKNLKEG-------TRGNDGGGGTSMVIQDGTTFEKGGVNVSVVYGQLSPAAVSAMKADHKNLRLPEDPKTGLP
QR-EAGGGGRSRVLRNGGVFEQAGVNFSHVHGEAMPASATAHRPELAGRSF--------QR-EEGGGGRSRVLADGDFLEQGGVNFSEVWGKSLPPSILKQRPEAEGHEF---------

H. sapiens
A. thaliana
C. reinhardtii
D. melanogaster
S. cerevisiae
E. coli
Synechocystis sp.

134
164
146
171
105
87
104

--GKLPFCAMGVSSVIHPKNPHAPTIHFNYRYFEVEEADGNKQ----WWFGGGCDLTPTY
--GPVPFFAAGVSSVLHPKNPFAPTLHFNYRYFETDAPKDVPGAPRQWWFGGGTDFTPAY
--GRVPFFAAGISSVMHPRNPHCPTMHFNYRYFETEEWNGIP---GQWWFGGGTDITPSY
--ASLPFFASGVSAVIHPRNPHVPTIHFNYRYFEVETAKGEKQ----WWFGGGTDLTPYY
VTDGVKFFACGLSMVIHPVNPHAPTTHLNYRYFETWNQDGTPQT---WWFGGGADLTPSY
-------EAMGVSLVVHPHNPYVPTSHANVRFFIAEK----PGADPVWWFGGGFDLTPFY
-------YATGTSMVLHPKNPYIPTVHLNYRYFEAG---------PVWWFGGGADLTPYY
*
*

H. sapiens
A. thaliana
C. reinhardtii
D. melanogaster
S. cerevisiae
E. coli
Synechocystis sp.

188
222
201
225
162
136
148

LNQEDAVHFHRTLKEACDQHGPDLYPKFKKWCDDYFFIAHRGERRGIGGIFFDDLD---IFEEDVKHFHSIQKQACDKFDPSFYPRFKKWCDDYFYIKHRDERRGLGGIFFDDLN---VVPEDMKHFHGTYKAVCDRHDPAYYEKFRTWCDEYFLIKHRGERRGLGGIFFDDLN---LCEKDASHFHQTLKSACDEHDPTYYPRFKKWCDDYFRIKHRNESRGIGGIFFDDID---LYEEDGQLFHQLHKDALDKHDTALYPRFKKWCDEYFYITHRKETRGIGGIFFDDYD---GFEEDAIHWHRTARDLCLPFGEDVYPRYKKWCDEYFYLKHRNEQRGIGGLFFDDLN---PFAEDAAHFHHTLKNACDQTHGEFYPVFKRWCDEYFYLKHRQEMRGIGGIFFDYQDGNAP
*
*

H. sapiens
A. thaliana
C. reinhardtii
D. melanogaster
S. cerevisiae
E. coli
Synechocystis sp.

244
278
257
281
218
192
208

----------------------SPSKEEVFRFVQSCARAVVPSYIPLVKKHCDDSFTPQE
----------------------DYDQEMLLSFATECANSVVPAYIPIVEKRKDMEFTEQH
----------------------DRNPEDILKFSTDAVNNVVEAYCPIIKKHMNDPYTPEE
----------------------SPNQEAAFNFVSSCARAVIPSYVPLVRKHKNREYGNNE
----------------------ERDPQEILKMVEDCFDAFLPSYLTIVKRRKDMPYTKEE
----------------------TPDFDRCFAFMQAVGKGYTDAYLPIVERRKAMAYGERE
LYRGPDPNGPAAQYSNQLAPIEPLGWEDLFSFAQRCGRAFLPAYSPIVEKRRNTEYGDRQ

282
316
295
319
256
230
268

KLWQQLRRGRYVEFNLLYDRGTKFGLFTPGSRIESILMSLPLTARWEYMHSPSENSKEAE
KAWQQLRRGRYVEFNLVYDRGTTFGLKTGG-RIESILVSLPLSARWEYDHKPEEGTEEWK
KEWQQIRRGRYVEFNLVYDRGTTFGLKTGG-RIESILMSMPQTASWLYDHQPKAGSPEAE
RQWQLLRRGRYVEFNLIYDRGTKFGLYTPGARYESILMSLPLHARWEYMHEPKSQSEEGK
QQWQAIRRGRYVEFNLIYDRGTQFGLRTPGSRVESILMSLPEHASWLYNHHPAPGSREAK
RNFQLYRRGRYVEFNLVWDRGTLFGLQTGG-RTESILMSMPPLVRWEYDYQPKDGSPEAA
RQFQLYRRGRYVEFNLVYDRGTIFGLQTNG-RTESILMSLPPLVRWQYCYSPEAGSPEAE
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H. sapiens
A. thaliana
C. reinhardtii
D. melanogaster
S. cerevisiae
E. coli
Synechocystis sp.
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H. sapiens
A. thaliana
C. reinhardtii
D. melanogaster
S. cerevisiae
E. coli
Synechocystis sp.
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Figure 2. Alignment of amino acid sequences of coproporphyrinogen oxidase from representative organisms. The amino acid sequence from
amino acids 82-341 of human coproporphyrinogen oxidase (Homo sapiens; accession BAA04033) is compared to coproporphyrinogen
oxidase from a plant (Arabidopsis thaliana; accession AAF86536), a green algae (Chlamydomonas reinhardtii; accession AAD28475), fruit
fly (Drosophila melanogaster; accession AAD46837), baker’s yeast (Saccharomyces cerevisiae; accession CAA89966), an enterobacteria
(Escherichia coli; accession BAA16325), and a cyanobacteria (Synechocystis sp.; accession BAA16863). Conserved amino acids are boxed in
black. The conserved histidines at positions 148, 158, 197, and 227 are boxed in gray and indicated by an asterisk. Sequence alignment
was generated using the BCM Search Launcher at Baylor College of Medicine (http://dot.imgen.bcm.tmc.edu:9331/multi-align/multi-align.
html) and the Boxshade server (http://www.ch.embnet.org/software/BOX_form.html).
The NcoI/HindIII fragment from expression vector
pHHCPO [3] was subcloned into the multiple cloning site
of pET21d. This resulted in expression of the cDNA encoding CPO to be under control of the lac operon. Production
of recombinant CPO is induced by the addition of IPTG.
Site-directed mutagenesis
Site-directed mutagenesis was performed using the PCR-mediated overlap extension method [22] utilizing three general oligonucleotides and a fourth mutagenic oligonucleotide.
Oligonucleotide #1 had the sequence 5’-CGCGGATCCAT

GGCTCACCATCACCATCACC-3’ and contained a NcoI restriction enzyme site (underlined). Oligonucleotide #2 had
the sequence 5’-TTGCAATACGGAACTTCCAGAATTTCA
GCTTCTTTGG-3’ and contained a 5’ non-complementary overhang of 10 nucleotides. Oligonucleotide #3 had the
sequence 5’-GGGGTACCAAGCTTATTCTGCCTGCATCA
ACGC-3’ and contained a HindIII restriction enzyme site
(underlined). Mutagenic oligonucleotides had the following sequences (alanine codons underlined): H148A; 5’-GG
GCGTGAGTTCTGTTATCGCCCCCAAGAATCCTCATG-3’,
H158A; 5’-CCTCATGCTCCTACGATCGCGTTCAACTACA
GATAC-3’, H197A; 5’-GAAGACGCTGTCCATTTTGCGCG
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Table 1. Kinetic constants of coproporphyrinogen oxidase for total product accumulated.
kcat (min–1)

kcat/Km

Coproporphyrinogen-III

0.3

3.6

12.0

Harderoporphyrinogen

1.2

7.9

6.6

Coproporphyrinogen-III

0.15

0.015

0.10

Harderoporphyrinogen

0.15

0.023

0.15

CACTCTGAAGGAGGC-3’, H227A; 5’-GATTACTTCTTTAT
AGCCGCCCGTGGAGAGCGGCGGGGC-3’.

Bacterial cell pellets were resuspended in 40 ml CPO lysis buffer (50 mM NaxPO4, 300 mM NaCl, 50 mM Tris, pH 7) containing 2.5 μg/ml leupeptin, 2 μg/ml chymostatin, 2 μg/ml
pepstatin, 1 μg/ml antipain, 10 μg/ml p-aminobenzamidine,
10 μg/ml benzamidine, and 0.2 mM phenylmethylsulfonylﬂuoride. Cells were lysed using a French Pressure cell at 20,000
psi, therefore addition of the detergent n-octyl-b-D-glucopyranoside, used previously by Medlock and Dailey [3], was unnecessary. We observed similar enzymatic activity for CPO in
the presence or absence of detergent (data not shown). After
centrifugation (100,000 × g for 30 min) the supernatant was
passed through a 4 ml column of TALON metal afﬁnity resin. The column was washed with 50 ml CPO lysis buffer, followed by 50 ml CPO lysis buffer containing 20 mM imidazole. Protein elution was accomplished by passing 10 ml of
CPO lysis buffer containing 250 mM imidazole (adjusted to
pH 7) through the column. Fractions of approximately 1 ml
each were collected. The protein concentration of each fraction was determined by the method of Bradford [23]. In all
cases, enzyme activities were measured for the supernatant
fraction as well as all fractions eluted from the column; activities for these various fractions were comparable for wildtype and mutant enzymes (data not shown).
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PCR was run using the following thermocycle parameters:
94°C 30 seconds, 55°C 30 seconds, 72°C 1 minute. Thirty
cycles were run in each PCR reaction. Three PCR reactions
were run for construction of each mutated cDNA. PCR reaction 1 employed oligonucleotides #1 and #2. Oligonucleotide
#1 anneals to the bottom strand (non-coding strand) at the
5’ end of the cDNA. Oligonucleotide #2 anneals to the top
strand (coding strand) near the 3’ end of the gene and contains 10 mismatched nucleotides at the 5’ end. PCR reaction 1 resulted in a DNA fragment that has a mismatch at
one end encoded in oligo 2, preventing extension from its
3’ end in subsequent PCR reactions, providing the basis for
selection of mutant CPO clones. PCR reaction 2 used oligonucleotide #3 and the desired mutagenic oligonucleotide,
and resulted in a DNA fragment complementary to the PCR
reaction 1 fragment. Template DNA for PCR 1 and PCR 2
was pET21d-CPO, the wild-type human CPO cDNA cloned
into pET21d. The encoded wild-type CPO lacked the amino terminal 33 amino acids that serve as a mitochondrial
targeting signal, and contained the amino terminal amino
acid sequence Met-Ala-His-His-His-His-His-His preceding
proline 34, serving as a 6x-His-tag for afﬁnity puriﬁcation
using a metal afﬁnity column. Following PCR 1 and 2, 10 μl
of each PCR reaction was run on a 0.7% agarose gel. The desired DNA fragments were puriﬁed from the gel and combined in a third PCR reaction employing oligonucleotides
#1 and #3. Each PCR product was digested with restriction
endonucleases NcoI and HindIII, followed by ligation with
NcoI/HindIII-digested pET21d. Each cDNA was sequenced
to verify the desired mutation had been incorporated.

U
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H158A Mutant Enzyme

Km (μM)

A
L

Wildtype Enzyme

Substrate
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Expression and puriﬁcation of His-tagged wild-type and
mutant CPO proteins
Escherichia coli strain BL21(DE3)RIL (Stratagene) was used as
expression host. One liter cultures containing pET21d-CPO
were grown in a shaking incubator at 37°C and 300 rpm to an
optical density of 0.8 at 600 nm in LB medium containing 50
μg/ml ampicillin and 34 μg/ml chloramphenicol. Induction
of protein expression was accomplished by the addition of
1 mM IPTG, followed by incubation at 37°C and 300 rpm
shaking for 3 hours. Cells expressing wild-type and mutant
forms of CPO were harvested by centrifugation at 4,620 × g
for 5 minutes. A considerable percentage of mutant enzyme
H197A was present in inclusion bodies when expression was
performed at 37°C. Therefore, upon induction with IPTG,
bacterial cultures expressing H197A were grown at 25°C, signiﬁcantly increasing the amount of soluble protein.

Substrate preparation
For enzyme assays, three different substrates (coproporphyrinogen-III, harderoporphyrinogen, and mesoporphyrinogen-VI) were used. The ﬁrst is the authentic substrate, while harderoporphyrinogen is the intermediary
monovinyl metabolite (Figure 1A). MesoporphyrinogenVI (meso’gen-VI) (Figure 1B) has been previously used to
assess the ability of chicken CPO to recognize variations in
ring substituents [4,5,24]. Use of the three substrates thus
allows for the relative comparison of rates for the ﬁrst and
second oxidative decarboxylation for both wild-type and
mutant enzymes. The substrates were prepared from the
corresponding porphyrin tetramethyl esters by treatment
overnight with 8.3 M HCl and reduction with 3% sodium
amalgam as previously reported [5,24]. CoproporphyrinIII tetramethyl ester was purchased from Aldrich Chemical
(Milwaukee, WI). Harderoporphyrin trimethyl ester and
mesoporphyrin-VI dimethyl ester were synthesized from
a,c-biladiene intermediates [24–26]. In all cases, the reduced porphyrinogens were used immediately following
reduction and quantitated spectrophotometrically at 406
nm in 8.3 M HCl. For time course experiments, substrates
were used in the range of 0.7 to 1 μM as the ﬁnal concentration in the enzyme incubations, concentrations above
the Km value for coproporphyrinogen III of 0.3 μM reported in this work (Table 1).
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Enzyme assay
Recombinant human CPO was assayed using the micro procedure reported by Jones et al. [27]. Brieﬂy, puriﬁed recombinant human CPO (300 μl of 50 μg/ml) was incubat-

Figure 3. (A) Purification of 6x-His-tagged wildtype CPO expressed
in E. coli. Lane 1: molecular weight standards (kDa), Lane 2:
100,000 × g supernatant (20 mg), Lane 3: metal affinity
column non-binding fraction (20 mg), Lanes 4–8: 250 mM
imidazole metal affinity column elution (1 μg, 2 μg, 4 μg,
8 μg, and 12 μg, respectively). (B) Purification of 6x-Histagged CPO mutant enzyme H148A expressed in E. coli. Lane
1: molecular weight standards (kDa), Lane 2: 100,000 × g
supernatant (20 μg), Lane 3: metal affinity column nonbinding fraction (20 μg), Lanes 4 and 5: 250 mM imidazole
metal affinity column elution (2 μg and 4 μg, respectively).
(C) Purification of 6x-His-tagged CPO mutant enzyme H158A
expressed in E. coli. Lane 1: molecular weight standards
(kDa), Lane 2: 100,000 × g supernatant (20 μg), Lane 3:
metal affinity column non--binding fraction (10 μg), Lanes
4 and 5: 250 mM imidazole metal affinity column elution (2
μg and 4 μg, respectively). (D) Purification of 6x-His-tagged
CPO mutant enzyme H197A expressed in E. coli. Lane 1:
molecular weight standards (kDa), Lane 2: whole cell lysate,
Lane 3: 100,000 × g pellet, Lane 4: 100,000 × g supernatant
(20 μg), Lane 5: metal affinity column non-binding
fraction (20 μg), Lanes 6 and 7: 250 mM imidazole metal
affinity column elution (0.5 μg and 4 μg, respectively). (E)
Purification of 6x-His-tagged CPO mutant enzyme H227A
expressed in E. coli. Lane 1: molecular weight standards
(kDa), Lane 2: 100,000 × g supernatant (20 μg), Lane 3:
metal affinity column non-binding fraction (20 μg), Lane 4:
metal affinity column 20 mM imidazole wash fraction, Lanes
5 and 6: 250 mM imidazole metal affinity column elution (4
μg and 2 μg, respectively).
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trophoretic purity was also evaluated, with results very similar to those shown for the wild-type enzyme with substantial
amounts of enzyme found in the soluble fraction and in the
250 mM elution fraction (Figure 3 B–E).
Catalysis by recombinant human CPO (wild-type)

A
L

For the human wild-type enzyme, the speciﬁc activities
(nmole product/min/mg protein) using the three different substrates were 4.9±0.9 for coproporphyrinogen-III,
5.1±1.8 for harderoporphyrinogen, and 1.7±0.7 for mesoporphyrinogen-VI (mean ±SD for n=5). Our data indicate
that the mesoporphyrinogen-VI is used much less efﬁciently
by the wild-type enzyme relative to the other two substrates.
This is in contrast to the chicken enzyme which apparently uses mesoporphyrinogen-VI and coproporphyrinogenIII with equal ability [24]. Using coproporphyrinogen-III,
there is little accumulation of the monovinyl product (harderoporphyrinogen) relative to the divinyl product (protoporphyrinogen-IX) at any incubation time, suggesting that
the ﬁrst decarboxylation is a slower process than the second
and thus may be the rate limiting event.
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ed with the freshly prepared substrates in the dark at 37°C.
For each prepared mutant, both wild-type and mutant enzymes were incubated under the same conditions so that
data are reported relative to wild-type activity. For each experiment, time courses for both wild-type and mutant enzymes were performed. Speciﬁc activities (nmole product
formed/min/mg protein) for the three different substrates
were determined under apparent initial velocity conditions.
Reactions were stopped by the addition of acetic acid: ethyl
acetate (3:7 v/v) and extracted into the ethyl acetate layer
as reported previously [27]. The porphyrins were converted
to their methyl esters and the substrate and product were
separated by HPLC using a partisil silica column and a mobile phase solvent of ethyl acetate: cyclohexane (35:65 v/v
for coproporphyrin-III and harderoporphyrin and 3:7 v/v
for mesoporphyrin-VI). Eluting porphyrins were detected
at 404 nm and percent product calculated from the integrated peak areas. When using coproporphyrinogen-III as
substrate, total product was calculated as the sum of the monovinyl and divinyl products. In all cases, results were compared to zero time incubations to correct for background.

Catalysis by recombinant human CPO mutant enzymes
For the four different histidine mutants, the ability to use
the three different substrates is indicated in Figure 4 as percent of wild-type speciﬁc activity. Mutant enzyme H148A,
though less active relative to wild-type enzyme under identical incubation conditions, still retained 39% of wild-type
activity for the overall conversion of coproporphyrinogenIII to protoporphyrinogen-IX. This is similar to the reduced
activity seen with harderoporphyrinogen as substrate (43%
of wild-type). A decrease in activity was also apparent for
the ﬁrst oxidative decarboxylation using mesoporphyrinogen-VI (21% of wild-type). This decrease in activity relative
to wild-type suggests His148 is not directly involved in catalysis but may play a structural role in CPO.

TI

Both the wild-type enzyme and the H158A mutant enzyme
were assayed under apparent initial velocity conditions with
two different substrates (coproporphyrinogen-III and harderoporphyrinogen) at various concentrations from 0.1 to
2.4 μM. Incubations were done under standard conditions
with 7.5 μg enzyme per incubate.

C
A

RESULTS

Expression and puriﬁcation of His-tagged human wildtype (WT) and mutant CPO proteins

U

To assess the level of endogenous bacterial activity, E. coli
cultures expressing a non-related recombinant enzyme
(Pseudomonas mevalonii HMG-CoA reductase) were analyzed. No coproporphyrinogen oxidase activity was detectable in the 250 mM imidazole elution fraction from the metal afﬁnity column (where the recombinant enzyme elutes).
Bacterial CPO activity was found in the 100,000 × g supernatant fraction and in the fraction that did not bind to the
afﬁnity column. Expression of recombinant wild-type human CPO in E. coli increased the activity in the supernatant fraction by approximately 500-fold compared to the
level of endogenous bacterial CPO activity in the control
culture. For all histidine mutants, CPO enzyme activities
in the 250 mM elution fraction were substantially higher
than that obtained using the Pseudomonas mevalonii HMGCoA reductase fractions.
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The inducible pET expression system (Novagen) resulted
in a large yield of recombinant wild-type CPO that was easily
puriﬁed using afﬁnity chromatography. An SDS-PAGE analysis of puriﬁcation fractions is shown in Figure 3A. Levels of
recombinant wild-type CPO were estimated to be as high as
30% of the total cellular protein. Yields of electrophoretically pure wild-type CPO were as high as 95 mg per liter of
bacterial culture. The large amounts of pure CPO obtainable using this expression system should facilitate future
studies of human CPO using biophysical methods that require large amounts of pure protein. For all mutants, elec-

Mutant enzyme H197A also retained the ability to efﬁciently catalyze the overall reaction (conversion of coproporphyrinogen-III to protoporphyrinogen-IX). The ability to catalyze the overall reaction at only 50% of the wild-type rate
is likely due to a decrease in the ability to perform the ﬁrst
oxidative decarboxylation, as estimated utilizing mesoporphyrinogen-VI as substrate. The second oxidative decarboxylation step was not impaired, with mutant enzyme H197A
retaining 100% of the wild-type activity using harderoporphyrinogen as substrate.
Interestingly, mutant enzyme H227A catalyzed the conversion of coproporphyrinogen-III to protoporphyrinogenIX at a rate almost twice that of the wild-type enzyme. The
increase in speciﬁc activity, relative to wild-type enzyme, of
the H227A mutant is illustrated by the ability of the mutant enzyme to use all three substrates better than wildtype enzyme. With the other three mutants, as well as the
wild-type human CPO, the ﬁrst oxidative decarboxylation
is the apparent rate limiting step for catalysis. However, for
H227A the ﬁrst oxidative decarboxylation no longer appears to be the rate limiting step when His227 is replaced
by alanine since the incubations with mesoporphyrinogenVI yielded higher speciﬁc activities than with either of the
other two substrates.
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Ratio of divinyl/monovinyl product formed
using coproporphyrinogen-III (5 min incubations)
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Figure 5. A comparison of the ratio of divinyl product formed to
monovinyl product formed using coproporphyrinogen-III as
substrate (after 5 min of incubation with 15 ug of enzyme,
at 37°C)
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Figure 4. A comparison of specific activities of mutant enzymes as
percent of wildtype specific activity using three different
substrates. Values are the average of 2 measurements.

similar abilities to produce a similar ratio of divinyl to monovinyl product as wild-type. However, the H158A mutant
yielded a much different ratio for these two products, producing substantially more of the monovinyl product than
the divinyl product. It would be of interest to evaluate these
histidine mutants using the A ring isomer coproporphyrinogen-IV (C-IV) for which it was previously shown that
increased levels of C-IV may be able to compete with the
authentic substrate. Such competition has important implications for clinical porphyrias [28].
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The mutant enzyme most catalytically impaired was that for
which His 158 was replaced by alanine. The ability of the
H158A mutant enzyme to catalyze the conversion of coproporphyrinogen-III to protoporphyrinogen-IX was decreased
some 50-fold. This decrease, while large, still reﬂects considerable enzyme activity, as the puriﬁed mutant enzyme
retained activity per mg of enzyme approximately 100-fold
greater than the baseline value for a control puriﬁcation
procedure conducted on cells expressing an unrelated protein, Pseudomonas mevalonii HMG-CoA reductase. The decrease in speciﬁc activity was attributable to impairment of
both the ﬁrst and second oxidative decarboxylations, with
the ﬁrst catalyzed at 9% of the wild-type and the second at
14% of the wild-type. In a previous study conducted using
recombinant mouse CPO, His158 was proposed to be essential for coordination of a metal ion, most likely Cu2+ [19].
Crude cell extracts of bacterial cultures, in which His 158
had been mutated to alanine in mouse CPO, resulted in no
detectable activity. Analysis of recombinant human CPO by
Medlock and Dailey, however, conclusively determined metal ions were not necessary for catalysis [3].
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There was little difference in the Km value for coproporphyrinogen III for mutant enzyme H158A as compared to
wild-type enzyme as shown in Table 1. However, when harderoporphyrinogen was used as substrate, there was an apparent difference in the Km value of the wild-type enzyme
and the mutant. This suggests alanine at position 158 has a
modest effect on the ability of CPO to bind substrate. There
was, however, a more substantial effect on the kcat value that
was especially evident with harderoporphyrinogen as substrate. The catalytic efﬁciency (kcat/Km) of the wild-type enzyme was substantially higher than that of the H158A mutant (Table 1) using either substrate.
An interesting consequence of replacing histidine 158 with
alanine was the relative ability of CPO to catalyze formation
of the monovinyl product (harderoporphyrinogen) relative
to the divinyl product protoporphyrinogen IX. In Figure 5
the ratio of divinyl product to monovinyl product using coproporphyrinogen-III is shown for the human wild-type enzyme and compared to the values for the various histidine
mutants. The H148A, H197A and H227A mutants all have

DISCUSSION
Location of conserved histidines 148, 197, and 227 in the
three-dimensional structure of human CPO
During completion of the work described here, three-dimensional structures of both Saccharomyces cerevisiae [29] and Homo
sapiens [30] coproporphyrinogen oxidase were determined.
In each case, the structure of CPO was reported to be dimeric. Phillips et al. [29] report the yeast CPO active-site is likely
a deep cleft lined by conserved amino acid residues and each
monomer has its own active-site. His158 of human CPO appears to be His133 of yeast CPO (in the S5 secondary structural region). The authors locate this region as perhaps one
side of the active site cleft. In human CPO [30], each monomer contains a central 7-stranded antiparallel beta sheet with
multiple helices present on each side of the sheet. A molecule of citrate is present in the crystallized enzyme, occupying a cleft near the dimer interface. The coordinate ﬁle for
the CPO monomer (PDB: 2AEX) was downloaded from the
protein database and analyzed, allowing us the opportunity
to probe the structural basis for our observations upon mutagenesis of the conserved histidines. Two of the conserved
histidines mutated in this study (His148 and His197) are present within the interior of the monomer. His148 is found at
the C-terminal end of b4 of the central seven-stranded beta
sheet while His197 is in the middle of a5, projecting from
this alpha helix into the interior of the monomer. His148 and
His 197, therefore, form a variety of atomic interactions that
are likely to play a role in maintaining the structural integrity of the monomer structure. These observations support
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CONCLUSIONS

Our data show that mutant forms of human coproporphyrinogen oxidase, where a conserved histidine residue at either position 148, 158, 197, or 227 is replaced by alanine,
are still catalytically competent. The level of activity remaining in the mutant forms of this enzyme is several orders of
magnitude greater than expected if only the histidine amino acid side chain was directly participating in catalysis.
Therefore, we conclude that these conserved histidine residues are not absolutely essential for the catalytic mechanism of human coproporphyrinogen oxidase but are likely to be important in maintaining the native conformation.
The large decrease in activity of the H158A mutant enzyme
supports the hypothesis that this amino acid is at or near
the active site of the enzyme, possibly reﬂecting an important role in maintaining the active site architecture of the
native enzyme. However, until the crystal structure of CPO
has been solved as an enzyme-substrate complex, the roles
of active site amino acids remain ambiguous.
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